U.S. P2Y12 Inhibitors Market
Description
P2Y12 receptor blockers are group of antiplatelet drugs. Antiplatelet are medicines that stop cells in the blood (platelets) from sticking together and forming a clot. A blood clot can lead to a heart attack or stroke. The P2Y12 receptor is a key player in platelet activation and represents an effective pharmacological target for the inhibition of platelet aggregation and prevention of atherothrombotic events. P2Y12 receptor blocker includes clopidogrel, ticlopidine, ticagrelor, prasugrel, and cangrelor drugs
Market Dynamics
Increasing prevalence of cardiovascular disease is expected to drive the market growth during the forecast period. For instance, according to data published in March 2019 by Florida Department of Health, responsible for the regulation of health practitioners for the preservation of the health, safety, and welfare of the public, stated that heart disease accounts for about two out of 10 deaths in Florida. Moreover, there were 80,402 coronary heart disease hospitalizations (including both angina and myocardial infarction) or an average of 220 coronary heart disease hospitalizations each day in 2018. Increasing government initiative to spread awareness regarding cardiovascular diseases is expected to drive the market growth over the forecast period. For instance, Million Hearts 2022, a national initiative co-led by Centers for Disease Control and Prevention and the Centers for Medicare & Medicaid Services to prevent one million heart attacks and strokes in five years. Moreover, the initiative focuses partner actions on a small set of priorities selected for their impact on heart disease, stroke, and related conditions.
Key features of the study
Market Dynamics
Increasing prevalence of cardiovascular disease is expected to drive the market growth during the forecast period. For instance, according to data published in March 2019 by Florida Department of Health, responsible for the regulation of health practitioners for the preservation of the health, safety, and welfare of the public, stated that heart disease accounts for about two out of 10 deaths in Florida. Moreover, there were 80,402 coronary heart disease hospitalizations (including both angina and myocardial infarction) or an average of 220 coronary heart disease hospitalizations each day in 2018. Increasing government initiative to spread awareness regarding cardiovascular diseases is expected to drive the market growth over the forecast period. For instance, Million Hearts 2022, a national initiative co-led by Centers for Disease Control and Prevention and the Centers for Medicare & Medicaid Services to prevent one million heart attacks and strokes in five years. Moreover, the initiative focuses partner actions on a small set of priorities selected for their impact on heart disease, stroke, and related conditions.
Key features of the study
- This report provides in-depth analysis of the U.S. P2Y12 inhibitors market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the U.S. P2Y12 inhibitors market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Mylan N.V., Bristol-Myers Squibb, Dr Reddy's Laboratories, Teva Pharmaceuticals USA, Inc., AstraZeneca, Genentech, Eli Lilly and Company, Panacea Biotec, CHIESI USA, Inc., Lupin, Cipla, and Biocon
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The U.S. P2Y12 inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. P2Y12 inhibitors market
- By Drug
- Clopidogrel
- Ticlopidine
- Ticagrelor
- Prasugrel
- Cangrelor
- Others
- By Route of Administration
- Oral
- Intravenous
- By Application
- Angioplasty
- Arterial Thrombosis
- Percutaneous Coronary Interventions
- Myocardial Infarction
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Key Players Insights
- Mylan N.V.
- Bristol-Myers Squibb
- Dr Reddy's Laboratories
- Teva Pharmaceuticals USA, Inc.
- AstraZeneca
- Genentech
- Eli Lilly and Company
- Panacea Biotec
- CHIESI USA, Inc.
- Lupin
- Cipla
- Biocon
Table of Contents
155 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug
- Market Snapshot, By Route of Administration
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Pipeline Analysis
- Regulatory Scenario
- PEST Analysis
- Epidemiology
- Product Launch/Approvals
- Acquisition, Collaboration & Agreements
- Key Developments
- Therapeutic Landscape
- 4. U.S. P2Y12 Inhibitors Market, By Drug, 2026 – 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Clopidogrel
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Ticlopidine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Ticagrelor
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Prasugrel
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Cangrelor
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- 5. U.S. P2Y12 Inhibitors Market, By Route of Administration, 2026 – 2033, (USD Bn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Intravenous
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- 6. U.S. P2Y12 Inhibitors Market, By Application, 2026 – 2033, (USD Bn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Angioplasty
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Arterial Thrombosis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Percutaneous Coronary Interventions
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Myocardial Infarction
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- 7. U.S. P2Y12 Inhibitors Market, By Distribution Channel, 2026 – 2033, (USD Bn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- 8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Dr Reddy's Laboratories
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Teva Pharmaceuticals USA, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Genentech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Panacea Biotec
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- CHIESI USA, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Lupin
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Cipla
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Biocon
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Analyst Views
- 9. Section
- Research Methodology
- About Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
